Lahore: BF Biosciences Limited has scheduled a meeting of its Board of Directors to discuss the company's quarterly financial results for the period ending on September 30, 2026. The meeting is set to take place on October 27, 2026, at 5:00 PM via video link.

The company's announcement, dated October 20, 2026, indicates that during this meeting, the board will also deliberate on any potential declaration of entitlement. In line with regulatory requirements, BF Biosciences has instituted a closed period from October 20, 2026, to October 27, 2026, as stipulated under Pakistan Stock Exchange (PSX) Regulation 5.6.4.

According to information available from the Pakistan Stock Exchange (PSX), this closed period is a standard procedure that prevents trading of the company's shares by its directors, executives, and employees who may have access to privileged information, ensuring transparency and fairness in the market.

BF Biosciences Limited operates within the designated market category of pharmaceuticals, engaging in the development and distribution of biopharmaceutical products. The forthcoming board meeting and financial review will provide insights into the company's performance and strategic direction for stakeholders and investors.